Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Key Stats

• Today's Range: $1.46 to $1.63
• 50-Day Range: $1.38 to $1.78
• 52-Week Range: $1.23 to $6.90
• Volume: 768,918 shs
• Average Volume: 800,655 shs
• Market Capitalization: $55.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 46% of companies evaluated by MarketBeat, and ranked 638th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Metagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Metagenomi has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Metagenomi is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Metagenomi is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.78% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Metagenomi has recently decreased by 11.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.78% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Metagenomi has recently decreased by 11.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.45

News Sentiment

Metagenomi has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Metagenomi this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

4 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,800.00 in company stock.

Percentage Held by Insiders

17.80% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

MGX Stock Analysis - Frequently Asked Questions

How have MGX shares performed this year?

Metagenomi's stock was trading at $3.61 on January 1st, 2025. Since then, MGX shares have decreased by 58.7% and is now trading at $1.49.
View the best growth stocks for 2025 here.

How were Metagenomi's earnings last quarter?

Metagenomi, Inc. (NASDAQ:MGX) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.06. The firm earned $4.13 million during the quarter, compared to the consensus estimate of $8.75 million. Metagenomi had a negative trailing twelve-month return on equity of 43.23% and a negative net margin of 134.27%.

When did Metagenomi IPO?

Metagenomi (MGX) raised $94 million in an initial public offering on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share.

Who are Metagenomi's major shareholders?

Top institutional shareholders of Metagenomi include Hhlr Advisors LTD. (0.40%), AQR Capital Management LLC (0.23%), Goldman Sachs Group Inc. (0.21%) and Nuveen LLC (0.17%). Insiders that own company stock include Brian C Thomas, Holdings A/S Novo, Sarah B Noonberg and Pamela Wapnick.
View institutional ownership trends.

How do I buy shares of Metagenomi?

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Metagenomi own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/11/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 236
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +772.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.25 million
• Net Margins: -134.27%
• Pretax Margin: -137.13%
• Return on Equity: -43.23%
• Return on Assets: -18.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.18
• Quick Ratio: 6.18

Sales & Book Value

• Annual Sales: $45.26 million
• Price / Sales: 1.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 37,381,000
• Free Float: N/A
• Market Cap: $55.70 million
• Optionable: N/A
• Beta: -0.33